Concepedia

Author

Andrés López

Vall d'Hebron Hospital UniversitariORCID

Also Known As

A López, A. Lopez, A. López, A. López, A.M. López, A.M. Álvarez López, Alexia Maria Fernandez Lopez, Ana Benítez López, Anayansi I. López, Andres Lopez

35

Publications

802

Citations

10

H-Index

18

Concepts

All Affiliations

Vall d'Hebron Hospital UniversitariHospital Clínico Universitario de ValenciaVall d'Hebron Institut de RecercaHospital Universitario La PazCharles University
AL

About

Andrés López is an author at Vall d'Hebron Hospital Universitari specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

86

2

Immunology

2

2

62

3

Cellular Therapies

1

1

46

4

Marrow Transplantation

1

1

46

5

Pathology

1

1

16

Andrés López

×

8

Publications

374

Citations

8

H-Index

YearCitations

GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study

Andrés López, Antonio Gutiérrez, Andrés Palacios,

European Journal Of Haematology

2007

110

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

Marek Trněný, Gregor Verhoef, Martin J.S. Dyer,

Haematologica

2018

60

Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

Noelia Purroy, Juan Bergua, Laura Gallur,

British Journal of Haematology

2014

56

Autologous stem cell transplantation for primary refractory Hodgkin’s disease: results and clinical variables affecting outcome

M. Constans, Anna Sureda, María José Terol,

Annals of Oncology

2003

46

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

José Mayordomo, Andrés López, Núria Viñolas,

Current Medical Research and Opinion

2009

45

Available evidence and outcome of off-label use of rituximab in clinical practice

Imma Danés, Antònia Agustí, Antonio Vallano,

European Journal of Clinical Pharmacology

2013

24

Synthesis and Anthelmintic Evaluation of Novel Valerolactam- Benzimidazole Hybrids

Beatriz Munguía, Pablo Mendina, Romina Espinosa,

Letters in Drug Design & Discovery

2013

17

Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).

Marek Trněný, Gregor Verhoef, Martin J.S. Dyer,

Journal of Clinical Oncology

2014

16

Page 1